[go: up one dir, main page]

PE20140236A1 - IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS - Google Patents

IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS

Info

Publication number
PE20140236A1
PE20140236A1 PE2013001976A PE2013001976A PE20140236A1 PE 20140236 A1 PE20140236 A1 PE 20140236A1 PE 2013001976 A PE2013001976 A PE 2013001976A PE 2013001976 A PE2013001976 A PE 2013001976A PE 20140236 A1 PE20140236 A1 PE 20140236A1
Authority
PE
Peru
Prior art keywords
imidazo
alkyl
methyl
triazines
treatment
Prior art date
Application number
PE2013001976A
Other languages
English (en)
Inventor
Thomas Allen Chappie
John Michael Humphrey
Patrick Robert Verhoest
Eddie Yang
Christopher John Helal
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45755439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140236(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PE20140236A1 publication Critical patent/PE20140236A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE IMIDAZO[5,1-f][1,2,4]TRIAZINAS DE FORMULA (I) DONDE AR5 ES UN COMPUESTO DE FORMULA A1R5, A2R5, ENTRE OTROS, EN DONDE R4 ES H, HALO, ALQUILO(C1-C6), ENTRE OTROS; R4a ES H, ALQUILO(C1-C6), ALQUENILO(C3-C4), ENTRE OTROS; R5 ES R5a, R5b, ENTRE OTROS, DONDE R6 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C15), ENTRE OTROS; R7 ES H, HALO, ALQUILO(C1-C6), CN, ENTRE OTROS; n ES DE 0 A 4; R1 ES H, ALQUILO(C1-C6), ALQUINILO(C2-C6), ENTRE OTROS; R2 ES CICLOALQUILO(C3-C15), ARILO(C6-C10), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-(AZETIDIN-1-IL)-7-METIL-5-[1-METIL-5-(4-METILFENIL)-1H-PIRAZOL-4-IL]IMIDAZO[5,1-f][1,2,4]TRIAZINA; 4-(AZETIDIN-1-IL)-7-METIL-5-{1-METIL-5-[4-(TRIFLUOROMETIL)FENIL]-1H-PIRAZOL-4-IL}IMIDAZO[5,1-f][1,2,4]TRIAZINA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA FOSFODIESTERASA 2 (PDE2) SIENDO UTILES EN EL TRATAMIENTO DEL DETERIORO COGNITIVO, ESQUIZOFRENIA, DEPRESION
PE2013001976A 2011-02-23 2012-02-09 IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS PE20140236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161445617P 2011-02-23 2011-02-23

Publications (1)

Publication Number Publication Date
PE20140236A1 true PE20140236A1 (es) 2014-03-14

Family

ID=45755439

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001976A PE20140236A1 (es) 2011-02-23 2012-02-09 IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS

Country Status (31)

Country Link
US (2) US8598155B2 (es)
EP (1) EP2681218A1 (es)
JP (1) JP5543039B2 (es)
KR (1) KR101548443B1 (es)
CN (1) CN103391941A (es)
AP (1) AP2013007070A0 (es)
AR (1) AR085304A1 (es)
AU (1) AU2012221828C1 (es)
BR (1) BR112013021366A2 (es)
CA (1) CA2825699A1 (es)
CL (1) CL2013002125A1 (es)
CO (1) CO6751271A2 (es)
CR (1) CR20130371A (es)
CU (1) CU20130107A7 (es)
DO (1) DOP2013000194A (es)
EA (1) EA022586B1 (es)
EC (1) ECSP13012892A (es)
GT (1) GT201300206A (es)
IL (1) IL227716A0 (es)
MA (1) MA34922B1 (es)
MX (1) MX2013009684A (es)
NI (1) NI201300071A (es)
PE (1) PE20140236A1 (es)
PH (1) PH12013501556A1 (es)
SG (1) SG192576A1 (es)
TN (1) TN2013000349A1 (es)
TW (1) TWI469983B (es)
UA (1) UA106692C2 (es)
UY (1) UY33916A (es)
WO (1) WO2012114222A1 (es)
ZA (1) ZA201306348B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022586B1 (ru) * 2011-02-23 2016-01-29 Пфайзер Инк. ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
GEP201706675B (en) 2013-05-02 2017-05-25 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
CN110092788B (zh) * 2014-04-23 2022-02-25 达特神经科学(开曼)有限公司 作为PDE2抑制剂的取代的[1,2,4]三唑并[1,5-a]嘧啶-7-基化合物
US10239882B2 (en) 2014-11-05 2019-03-26 Dart Neuroscience (Cayman) Ltd. Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors
RU2702732C1 (ru) 2014-12-06 2019-10-10 Интра-Селлулар Терапиз, Инк. Органические соединения
HK1243936A1 (zh) 2014-12-06 2018-07-27 Intra-Cellular Therapies, Inc. 有机化合物
CN104525240A (zh) * 2014-12-10 2015-04-22 河北工业大学 硝酸铁作为催化剂在苯与羟胺盐反应一步法制苯胺反应中的应用方法
EP3237401B1 (en) 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
US10287269B2 (en) 2015-03-26 2019-05-14 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
EP3291817B1 (en) 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
US10647727B2 (en) 2015-06-25 2020-05-12 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
JP6872541B2 (ja) 2015-11-02 2021-05-19 ヤンセン ファーマシューティカ エヌ．ベー． ［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−イル化合物
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
JP7018944B2 (ja) 2016-11-02 2022-02-14 ヤンセン ファーマシューティカ エヌ．ベー． ＰＤＥ２阻害剤としての［１，２，４］トリアゾロ［１，５－ａ］ピリミジン化合物
SG11201903892UA (en) 2016-11-02 2019-05-30 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
EA039102B1 (ru) 2016-11-02 2021-12-03 Янссен Фармацевтика Нв Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2
AU2018207776B2 (en) 2017-01-10 2021-06-17 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
AR113206A1 (es) 2017-01-10 2020-02-19 Bayer Cropscience Ag Derivados heterocíclicos como pesticidas
CA3083176A1 (en) 2017-11-23 2019-05-31 Oslo University Hospital Hf Treatment of tachycardia
CN108640923A (zh) * 2018-07-09 2018-10-12 湖南天地恒制药有限公司 一种托法替布关键中间体的制备方法
WO2020086650A2 (en) * 2018-10-23 2020-04-30 Intra-Cellular Therapies, Inc. Novel compounds
US11492362B1 (en) 2022-02-17 2022-11-08 King Abdulaziz University Pyridine derivatives for the treatment of hyperproliferative diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4035893A (en) * 1991-12-17 1993-07-19 Upjohn Company, The 3-substituted imidazo (1,5-a) and imidazo (1,5-a)-triazolo (1,5-c) quinoxalines and quinazolines with cns activity
YU59100A (sh) * 1999-10-11 2003-10-31 Pfizer Inc. Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
WO2005041957A1 (en) * 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
AP2139A (en) 2004-04-02 2010-08-21 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
MY139689A (en) * 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
CA2591991C (en) * 2005-01-05 2013-11-19 Altana Pharma Ag Triazolophthalazines
JP4302762B2 (ja) 2005-01-07 2009-07-29 ファイザー・プロダクツ・インク 複素環式芳香族キノリン化合物およびｐｄｅ１０阻害剤としてのその使用
PL1951724T3 (pl) 2005-11-17 2011-09-30 Osi Pharmaceuticals Llc SKONDENSOWANE BICYKLICZNE INHIBITORY mTOR
WO2007087395A2 (en) 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
PL2529622T3 (pl) 2006-09-22 2018-07-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
EP2178563A2 (en) 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
US7683575B2 (en) 2007-07-18 2010-03-23 Tesla Motors, Inc. Method and apparatus for identifying and disconnecting short-circuited battery cells within a battery pack
BRPI0910232A2 (pt) 2008-03-19 2015-09-29 Osi Pharm Inc formas de sais inibidores do mtor
JP2011520970A (ja) 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
CN102471292A (zh) 2009-07-09 2012-05-23 Osi药物有限责任公司 取代的3-氨基-5-氧代-4,5-二氢-[1,2,4]三氮烯的方法
AU2011269788B2 (en) 2010-02-03 2015-12-10 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-Met inhibitors
EA022586B1 (ru) * 2011-02-23 2016-01-29 Пфайзер Инк. ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ

Also Published As

Publication number Publication date
MX2013009684A (es) 2013-10-28
AU2012221828B2 (en) 2015-05-28
BR112013021366A2 (pt) 2016-09-13
EA022586B1 (ru) 2016-01-29
AP2013007070A0 (en) 2013-08-31
UY33916A (es) 2012-09-28
EP2681218A1 (en) 2014-01-08
PH12013501556A1 (en) 2017-10-25
EA201390971A1 (ru) 2014-02-28
KR101548443B1 (ko) 2015-08-28
CR20130371A (es) 2013-09-18
JP5543039B2 (ja) 2014-07-09
CU20130107A7 (es) 2013-09-27
WO2012114222A1 (en) 2012-08-30
TN2013000349A1 (fr) 2015-01-20
CO6751271A2 (es) 2013-09-16
GT201300206A (es) 2015-02-19
AR085304A1 (es) 2013-09-18
UA106692C2 (uk) 2014-09-25
ZA201306348B (en) 2014-04-30
DOP2013000194A (es) 2014-01-31
US9200000B2 (en) 2015-12-01
JP2014506589A (ja) 2014-03-17
TWI469983B (zh) 2015-01-21
CA2825699A1 (en) 2012-08-30
CN103391941A (zh) 2013-11-13
AU2012221828C1 (en) 2015-10-01
US8598155B2 (en) 2013-12-03
ECSP13012892A (es) 2013-10-31
CL2013002125A1 (es) 2013-12-20
US20120214791A1 (en) 2012-08-23
MA34922B1 (fr) 2014-02-01
NI201300071A (es) 2014-02-12
US20140066622A1 (en) 2014-03-06
IL227716A0 (en) 2013-09-30
KR20130132612A (ko) 2013-12-04
TW201247673A (en) 2012-12-01
SG192576A1 (en) 2013-09-30
NZ613373A (en) 2015-04-24

Similar Documents

Publication Publication Date Title
PE20140236A1 (es) IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS
PE20141686A1 (es) Compuestos de piperazina alquilados como inhibidores de actividad btk
PE20151538A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
AR077975A1 (es) Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EA201291236A1 (ru) Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
UY34219A (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
EA201100749A1 (ru) Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10
PE20142294A1 (es) Compuestos de indol e indazol que activan la ampk
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
MX361020B (es) Procesos para preparar compuestos heterociclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo [3,2,1]octano-2-carboxam ida y sales de la misma.
MX2011011875A (es) Compuesto de carboxamida heterociclica diamino.
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
TW200639166A (en) Amino-pyridines as inhibitors of β-secretase
PH12015502705B1 (en) Processes of making and crystalline forms of a mdm2 inhibitor
TN2011000404A1 (en) Fused pyrimidines
MX358376B (es) Nuevos derivados dihidroquinolina-2-ona.
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
EA201070864A1 (ru) Новые гетероциклические соединения
PE20151535A1 (es) Derivado de dihidropiridazin-3,5-diona
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
EA201171211A1 (ru) Производные оксадиазола
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ

Legal Events

Date Code Title Description
FD Application declared void or lapsed